| 8.24 0.06 (0.73%) | 07-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.96  |
1-year : | 11.63 |
| Resists | First : | 8.52 |
Second : | 9.96 |
| Pivot price | 7.12 |
|||
| Supports | First : | 6.96 |
Second : | 6 |
| MAs | MA(5) : | 8.01 |
MA(20) : | 6.97 |
| MA(100) : | 6.37 |
MA(250) : | 5.57 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 87.6 |
D(3) : | 86.3 |
| RSI | RSI(14): 68.2 |
|||
| 52-week | High : | 8.81 | Low : | 3.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DTIL ] has closed below upper band by 10.4%. Bollinger Bands are 57.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.54 - 8.57 | 8.57 - 8.61 |
| Low: | 7.87 - 7.91 | 7.91 - 7.94 |
| Close: | 8.18 - 8.24 | 8.24 - 8.3 |
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Mon, 06 Jul 2026
Enterprise value to revenue forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Wed, 01 Jul 2026
Precision BioSciences (NASDAQ: DTIL) shares HBV data, DMD trial timeline - Stock Titan
Mon, 29 Jun 2026
Index Expanding Market Visibility with Institutional Investors - Business Wire
Tue, 16 Jun 2026
Precision BioSciences (NASDAQ: DTIL) amends loan and extends term to 2029 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 2.001e+007 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 1,510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.774e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -96.8 % |
| Operating Margin | -83.8 % |
| Return on Assets (ttm) | -18.3 % |
| Return on Equity (ttm) | -71 % |
| Qtrly Rev. Growth | 37 % |
| Gross Profit (p.s.) | 212.81 |
| Sales Per Share | 3.52109e+007 |
| EBITDA (p.s.) | 3.52109e+007 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 3.57 |
| Dividend | 0 |
| Forward Dividend | 1.94e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|